Acyclovir concentrations in serum and cerebrospinal fluid at steady state

Area of Science:

• Pharmacology
• Neurology
• Clinical Trials

Background:

• Multiple sclerosis (MS) is a chronic neurological disease.
• Acyclovir is being investigated for its therapeutic potential in MS.
• Understanding drug penetration into the central nervous system is crucial for MS treatment.

Purpose of the Study:

• To assess acyclovir concentrations in serum and cerebrospinal fluid (CSF) during long-term oral therapy in multiple sclerosis (MS) patients.
• To evaluate the stability and penetration of acyclovir across the blood-brain barrier in MS.
• To determine if acyclovir accumulates in the CSF with prolonged treatment.

Main Methods:

• A long-term clinical trial involving oral acyclovir (800 mg tid) in MS patients.
• Paired serum and CSF samples collected at multiple time points (1, 4, 8, 12 months) during treatment.
• Acyclovir concentrations measured by radioimmunoassay.
• Pharmacokinetic analysis of acyclovir in serum and CSF.

Main Results:

• CSF acyclovir concentrations were stable (mean 0.83 microM) compared to variable serum levels (mean peak 4.08 microM, trough 2.47 microM).
• CSF acyclovir levels were minimally affected by serum fluctuations.
• The acyclovir CSF/serum ratio was consistent, suggesting the blood-brain barrier function was not significantly impacted.
• No evidence of acyclovir accumulation in CSF after 1-12 months of treatment.

Conclusions:

• Oral acyclovir demonstrates stable concentrations in the CSF of MS patients during long-term therapy.
• Acyclovir penetration into the CSF is relatively consistent and not significantly influenced by serum level fluctuations or blood-brain barrier integrity.
• Long-term oral administration of acyclovir does not lead to accumulation in the CSF for MS patients.